The overarching goal of the CCP is to reduce cancer incidence and improve cancer outcomes by generating new knowledge about the genetic, behavioral and health care determinants of cancer risk and outcomes and the effectiveness of strategies for reducing risk and improving outcomes. Because the breadth of research encompassed under this goal is large, CCP leadership has identified several key areas for scientific emphasis based upon the ACC strategic plan, scientific opportunities, and program member interests and strengths. These areas have remained stable over the last several years;however, these priorities will be reexamined with the recruitment of new program leadership and through the new strategic vision for the ACC with the recruitment of Dr. Dang as the ACC Director. These areas of emphasis are organized as research themes and include:Communication and behavior change, Disparities, Genetics, Health care outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593263
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$117,626
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Zhang, Zi; Brown, Justin C; O'Malley Jr, Bert W et al. (2016) Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma. Support Care Cancer 24:2333-40

Showing the most recent 10 out of 848 publications